Levels of Raltegravir in the Female Genital Tissue

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2012

Conditions

HIV

Interventions

DRUG

Raltegravir

Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)

Trial Locations (1)

University of Washington, Clinical Research Center, Seattle

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Washington

OTHER

NCT01327482 - Levels of Raltegravir in the Female Genital Tissue | Biotech Hunter | Biotech Hunter